share_log

SciSparc | 20-F/A: Registration statement / Annual report / Transition report (Amendment)

SciSparc | 20-F/A: Registration statement / Annual report / Transition report (Amendment)

SciSparc | 20-F/A：年度報告/過渡報告/註冊聲明(修正)
美股SEC公告 ·  05/02 21:23

Moomoo AI 已提取核心訊息

SciSparc Ltd., a pharmaceutical company, reported its annual financial performance for the fiscal year ended December 31, 2023. The company, which specializes in the development of cannabinoid-based therapeutics, did not generate revenue from its drug development segment but reported revenues of $2,879,000 from online sales of hemp-based products. The cost of goods sold amounted to $683,000, resulting in a gross profit of $2,196,000. Research and development expenses totaled $1,641,000, while general and administrative expenses reached $5,031,000. The company also recorded an impairment of intangible assets amounting to $1,042,000. SciSparc experienced a net loss of $5,883,000 for the year, with a basic and diluted loss per share of $14.43. The company's share of losses from equity-accounted investments was $210,000. Finance income, primarily from changes in the fair value of financial liabilities, was $2,219,000, and finance expenses, including losses from the remeasurement of investments in financial assets, were $1,055,000. The company's future plans include continuing its drug development efforts and expanding its online sales of hemp-based products.
SciSparc Ltd., a pharmaceutical company, reported its annual financial performance for the fiscal year ended December 31, 2023. The company, which specializes in the development of cannabinoid-based therapeutics, did not generate revenue from its drug development segment but reported revenues of $2,879,000 from online sales of hemp-based products. The cost of goods sold amounted to $683,000, resulting in a gross profit of $2,196,000. Research and development expenses totaled $1,641,000, while general and administrative expenses reached $5,031,000. The company also recorded an impairment of intangible assets amounting to $1,042,000. SciSparc experienced a net loss of $5,883,000 for the year, with a basic and diluted loss per share of $14.43. The company's share of losses from equity-accounted investments was $210,000. Finance income, primarily from changes in the fair value of financial liabilities, was $2,219,000, and finance expenses, including losses from the remeasurement of investments in financial assets, were $1,055,000. The company's future plans include continuing its drug development efforts and expanding its online sales of hemp-based products.
製藥公司ScisPARC Ltd. 報告了截至2023年12月31日的財年的年度財務業績。該公司專門開發基於大麻素的療法，其藥物開發部門沒有創造收入，但報告稱，大麻類產品的在線銷售收入爲2879,000美元。商品銷售成本爲68.3萬美元，毛利爲219.6萬美元。研發費用總額爲1,641,000美元，而一般和管理費用達到5,031,000美元。該公司還記錄了總額爲1,042,000美元的無形資產減值。ScisPARC全年淨虧損58.3萬美元，基本和攤薄後的每股虧損爲14.43美元。該公司的股票入賬投資虧損份額爲21萬美元。主要來自金融負債公允價值變動的財務收入爲2,219,000美元，包括金融資產投資調整損失在內的財務支出爲1,055,000美元。該公司的未來計劃包括繼續開展藥物開發工作和擴大大麻類產品的在線銷售。
製藥公司ScisPARC Ltd. 報告了截至2023年12月31日的財年的年度財務業績。該公司專門開發基於大麻素的療法，其藥物開發部門沒有創造收入，但報告稱，大麻類產品的在線銷售收入爲2879,000美元。商品銷售成本爲68.3萬美元，毛利爲219.6萬美元。研發費用總額爲1,641,000美元，而一般和管理費用達到5,031,000美元。該公司還記錄了總額爲1,042,000美元的無形資產減值。ScisPARC全年淨虧損58.3萬美元，基本和攤薄後的每股虧損爲14.43美元。該公司的股票入賬投資虧損份額爲21萬美元。主要來自金融負債公允價值變動的財務收入爲2,219,000美元，包括金融資產投資調整損失在內的財務支出爲1,055,000美元。該公司的未來計劃包括繼續開展藥物開發工作和擴大大麻類產品的在線銷售。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間